SCHEMBL721585

SCHEMBL721585

CC1=NS(=O)(=O)c2ccc(Cl)cc2N1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCC8 Q09428 3/20 0.79
KCNJ11 Q14654 3/20 0.79
ALDH1A1 P00352 2/20 0.79
CYP1A2 P05177 2/20 0.79
LMNA P02545 1/20 0.79
CYP3A4 P08684 1/20 0.79
CYP2D6 P10635 1/20 0.79
THRB P10828 1/20 0.79
TSHR P16473 1/20 0.79
SMN1; SMN2 Q16637 1/20 0.79
CA1 P00915 3/20 0.62
CA2 P00918 3/20 0.62
CA12 O43570 2/20 0.62
CA9 Q16790 2/20 0.62
HTR1A P08908 1/20 0.42
CHEK1 O14757 1/20 0.41
DAPK3 O43293 1/20 0.41
MAP4K4 O95819 1/20 0.41
RET P07949 1/20 0.41
PIM1 P11309 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diazoxide SCHEMBL41255 0.88 ABCC8 (1.00) ABCC8KCNJ11ALDH1A1CYP1A2LMNA
Diazoxide SCHEMBL31112206 0.88 ABCC8 (1.00) ABCC8KCNJ11ALDH1A1CYP1A2LMNA
SCHEMBL7601849 0.84 CA1 (0.64) ABCC8KCNJ11ALDH1A1CYP1A2LMNA
SCHEMBL7950905 0.84 ABCC8 (0.56) ABCC8KCNJ11ALDH1A1CYP1A2LMNA
SCHEMBL8284063 0.81 CA1 (0.60) ABCC8KCNJ11ALDH1A1CYP1A2LMNA
SCHEMBL718987 0.81 CYP3A4 (0.71) ABCC8KCNJ11ALDH1A1CYP1A2LMNA
SCHEMBL24050733 0.80 ABCC8 (0.53) ABCC8KCNJ11ALDH1A1CYP1A2LMNA
SCHEMBL719962 0.78 CYP3A4 (0.67) ABCC8KCNJ11ALDH1A1CYP1A2LMNA
SCHEMBL718730 0.78 CYP3A4 (0.67) ABCC8KCNJ11ALDH1A1CYP1A2LMNA
SCHEMBL721406 0.78 CA1 (0.55) ABCC8KCNJ11ALDH1A1CYP1A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053172-A1 USE OF A COMBINATION OF DIAZOXIDE AND METFORMIN FOR TREATING OBESITY OR OBESITY RELATED DISORDERS COOPERATIEVE MIRZORG U.A. 2012-03-01 US disclosed
US-20100234362-A1 USE OF DIAZOXIDE FOR SUPPRESSING THE PLASMA INSULIN LEVEL IN A MAMMAL COOPERATIEVE MIRZORG U.A. (NL) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053172-A1 USE OF A COMBINATION OF DIAZOXIDE AND METFORMIN FOR TREATING OBESITY OR OBESITY RELATED DISORDERS GPR119, KCNJ1, GLP1R ABCC8 317/4885KCNJ11 6/4885ALDH1A1 1266/4885
US-20100234362-A1 USE OF DIAZOXIDE FOR SUPPRESSING THE PLASMA INSULIN LEVEL IN A MAMMAL KCNN4, KCNN1, GPR119 ABCC8 524/4885KCNJ11 10/4885ALDH1A1 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.